Sat Kartar Life Limited · NSE:SATKARTAR
Sat Kartar Life — H2 FY26 Earnings Presentation
35 slides from Sat Kartar Life's earnings presentation, May 6, 2026
Slide 1: Intimation under Regulation 30 - Investors' Presentation
SAT KARTAR LIFE LIMITED (Formerly known as Sat Kartar Shopping Limited) Dated: 06.05.2026 To, The Manager- Listing Compliance National Stock Exchange India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla complex, Bandra (E), Mumbai 400051 SYMBOL: SATKARTAR ISIN: INE0NB801022 Sub: Intimat
Slide 2: Sat Kartar Life Ltd - Investor Presentation H2 & FY26
Sat Kartar Life Ltd Revolutionizing Wellness with Ayurveda Investor Presentation H2 & FY26
Slide 3: Ayurveda: The Science of Life
AYURVEDA The Science of Life
Slide 4: From the Promoter's Desk
From the Promoter’s Desk As we move through the second half of FY26, Sat Kartar Life Ltd. has entered a pivotal phase in its growth journey. The launch of our first Sat Kartar Ayurveda Hospital marks our expansion of the business into an integrated Ayurveda healthcare enterprise, combining products,
Slide 5: About
About We are more than a brand; we are your partner in a healthier journey, inspired by Ayurveda and backed by science. At Sat Kartar Life Ltd (formerly Sat Kartar Shopping Ltd), we are dedicated to promoting a healthier, more balanced lifestyle through the timeless wisdom of Ayurveda. As a modern A
Slide 6: Sat Kartar: Snapshot
Sat Kartar: Snapshot 01 02 03 04 05 30 Beds 28.72% / 38.7% 2500+ 25,000 16+ Remedial Ayurvedic Hospital ROE / ROCE Team Strength Daily Unique Leads Solutions 06 07 08 09 10 In house Formulations 160+ Pan-India In house Manufacturing of approved by Ministry SKUs Presence R&D Nutraceuticals of AYUSH 5
Slide 7: Key Half Yearly Highlights
Key Half Yearly Highlights SAT KARTAR SHOPPING LTD TRANSITIONED TO SAT KARTAR LIFE LTD. Strategic Healthcare Technology Expansion 02 Advancement 04 Entered into a 3-year strategic Our AI initiatives are directly MOU (April 2026) with Jeena linked to measurable outcomes, Sikho Lifecare Limited to inc
Slide 8: Strategic Collaboration: Sat Kartar Life x Jeena Sikho Lifecare
Strategic Collaboration Announcement SAT KARTAR LIFE LTD × JEENA SIKHO LIFECARE LTD 01 03 05 Overview Synergy Highlights Vision Entered into a JSL: Network of Build a scalable, strategic MoU to Ayurveda hospitals & accessible build a technology- Panchakarma centres Ayurveda enabled Ayurveda SKL: AI-
Slide 9: Capital Raise & Healthcare Ecosystem Expansion
Capital Raise & Healthcare Ecosystem Expansion Strategic Fundraise Initiative – Approved preferential issue at ₹172 per equity share/warrant, including equity shares and convertible warrants, to accelerate growth and strengthen the integrated healthcare platform. Institutional Investor Participation
Slide 10: Our Care and Support To Your Problems
Our Care and Support To Your Problems 80% Sexual Wellness Diabetes Piles Care De- Addictions Bone & Joints Revenue Contribution PCOS Respiratory Hair Liver Infertility Mind Immune Lungs Personal 20% PCOD Support Care Care Support Care Support Care Care Revenue Contribution 9
Slide 11: Sat Kartar Sanjeevan Ayurveda Specialty Hospital - Key Highlights
Sat Kartar Sanjeevan AYURVEDA SPECIALTY HOSPITAL – KEY HIGHLIGHTS Well Established Ayurveda Specialty Hospital Built across 13,500 Sq. Feet Bed Capacity- 30 Beds ₹2 Cr Investment (Internal Accruals + IPO Funds) Operational w.e.f. March 5,2026 To contribute meaningfully to Revenue and EBITDA as healt
Slide 12: Sat Kartar Hospital's Capital-Efficient Healthcare Model
Sat Kartar Hospital’s Capital-Efficient Healthcare Model Panchkarma Therapies: Hospitals are equipped with: Detoxification & metabolic Consultation Rooms restoration Therapy Rooms Kshar Sutra for Piles: Minimally Recovery Rooms invasive Ayurvedic procedure Procedure Room Kidney Support Therapies: Sp
Slide 13: Hospital Growth Roadmap
Hospital Growth Roadmap SCALING CAPACITY WITH REVENUE VISIBILITY 04 Capacity Scale-Up: 30 beds in FY26, expanding to 300 beds by FY27E, and 1000 beds by FY28E 03 Revenue Contribution: Hospitals expected to contribute ₹100+ Cr by FY28, emerging as a key growth driver 02 3.33x 1000 Beds Margin Expansi
Slide 14: Healing Across Our Presence
Healing Across OUR PRESENCE North India : 42.4% We operate and ensure availability of South India : 57.6% our products all over India South India is a key growth market, led by Tamil Nadu’s contribution We serve to more than 12,000+ Pincodes across India Top Revenue Contributing States: Our marketin
Slide 15: The Team Driving Growth
The Team Driving Growth A Team That Speaks Wellness in Every Vernacular Language. 2500+ Strong Workforce Multilingual Reach Languages: 1.Hindi Ayurveda First 2.Kannada 3.Tamil Our focus on Ayurveda ensures we stay rooted in 4.Telugu Multilingual natural and holistic 5.Bengali Support Teams wellness.
Slide 16: Sat Kartar Growth Formula
Sat Kartar Growth Formula ASSET-LIGHT LEVERAGING ECONOMIES OPERATING HIGH STRONG BRAND MODEL & DATA DATABASE OF OF SCALE LEVERAGE RETENTION & POSITIONING & DRIVEN 30+MILLION CONVERSION PRODUCT CONSUMERS RATIO INNOVATION Company's major focus is to be asset light and Grow without heavy assets keeping
Slide 17: Our Growth Strategy
Our Growth Strategy Horizontal Expansion Ayurvedic hospitals already launched; further expansion into yoga therapy and integrated wellness clinics underway. Hyper-Personalized Wellness AI-driven recommendations for 30M+ users, tailored by ailment, age, region, and behavior to improve outcomes and en
Slide 18: ₹500+ Cr Revenue Target - Way Forward
Way Forward OUR FY27-FY28 GROWTH ROADMAP Healthcare Platform (Topping – Upside to ₹500 Cr) 30 to 300 beds by FY27. Products business to be pushed ₹500+ Cr Revenue Target by Product Segments through OPD + pharmacy model. Hospitals expected to By FY28, we remain confident to outpace industry growth by
Slide 19: Keeping the Spirit of Ayurveda Alive
KEEPING THE SPIRIT OF Ayurveda Alive
Slide 20: Our Journey So Far - From Roots to Reach
Our Journey So Far - From Roots to Reach 2022 2026 2018 Revenue Milestone: 50 Crores 1.Announced collaboration with Digital Marketing Initiation Jeena Sikho Lifecare Ltd for Ayurveda healthcare opportunities. 2024 2.Inaugurated Sat Kartar Ayurvedic IPO Application Post Hospital. Revenue milestone of
Slide 21: From Research To Delivery: Our Product Journey
From Research To Delivery: Our Product Journey Data reviewed and Decision Developing and Approving Manufacturing by the Customers inquiring and taken by Senior Management of Marketing Strategy Contract Manufacturers ordering product Strategic decision- Crafting and approving Launching product Custom
Slide 22: Asset Light Model
Asset Light Model FOCUSING ON ASSET LIGHT BUSINESS MODEL AND HIGHER RETURN RATIOS Strategic Contract Manufacturing Quality Assurance We follow a strategic contract Through robust contracts, we retain manufacturing approach: control over: Partnering with trusted third-party Proprietary Ayurvedic form
Slide 23: Product Portfolio
Product Portfolio Product Portfolio Specific problem led niche Lifestyle led Curative therapeutic area Areas Addiction Sexual Wellness Piles Immunity Care Diabetes Hair fall Personal Care Bone and Joint Mind Care These nutraceutical products are set to be pain manufactured and marketed in the USA. P
Slide 24: Product Portfolio: Bones and Joints, Sexual Wellness, Piles
Product Portfolio Bones and Joints Provides relief from muscle stiffness Helps reduce excruciating joint pain Instant and long-lasting results Sexual Wellness Piles Boosts testosterone & increases sperm count. Stimulates the nervous system. Supports, assists under Ayurveda Provides stamina and boost
Slide 25: Product Portfolio: Addiction, Diabetes, Others
Product Portfolio Addiction Suppresses addiction cravings. Purifies and detoxifies blood No withdrawals or relapse symptoms. Strengthens vital organs. Diabetes Stimulates secretion from Pancreatic beta -Cells Others Boosts acceptance of glucose metabolizing hormones. Normalises blood sugar. Fertilit
Slide 26: Plantomed Neutraceuticals Private Limited
Plantomed Neutraceuticals Private Limited BRAND CONSOLIDATION AND PRODUCT EXPANSION. Low Ticket Size Affordable product pricing enables wider accessibility and higher volume sales. Status Acquired an additional 24% stake, thereby High Retention F I TS E making it a wholly owned subsidiary. IC BEN St
Slide 27: In-House Capsule Manufacturing Facility
Sat Kartar Life Ltd IN-HOUSE CAPSULE MANUFACTURING FACILITY Enhanced Quality Control Reduced dependency on third-party quality Manufacturing Facility of assurance and better control over raw SatKartar Life Ltd materials. Sonipat, Haryana Operational Efficiency Directly fulfills 50% of capsule Planne
Slide 28: Our Premium Wellness Brand
Our Premium Wellness Brand VENTURING INTO HIGH MARGIN PRODUCT VERTICALS ~ Vedabay Vitili-Go Vedabay Testo Vedabay Safed Musli Vedabay Vedabay Ayush 82 Build Psory Sys Vedabay Lungs Detox Vedabay Vedabay Liver Detox Vedabay Glutathione Stop Piles De-Varicose Tablets 27
Slide 29: Industry Overview: The Science of Life
INDUSTRY OVERVIEW The Science of Life
Slide 30: Industry Overview
Industry Overview Ayurvedic Sector (In $Billion) Medical Tourism Medical Tourism (India) (Global) Global Indian The Ayurvedic sector is growing rapidly, driven by 52 Source : Grand View Research, IBEF, WHO & IMARC rising demand for natural and preventive healthcare. In India, it is expected to expan
Slide 31: Bridging Ancient Wisdom With Modern Science
Bridging Ancient Wisdom With Modern Science OUR TEAM OF MEDICAL CONSULTANTS Dr. Hindika Bhagat Dr. Ravinder Kaur Dr. Dipti Jain Dr. Abhinesh Tiwari Dr. Pooja Verma Dr. Meghna Attray Experience: 8+ Years Experience: 23+ Years Experience: 22+ Years Experience: 5+ Years Experience: 5+ Years Experience:
Slide 32: Financials
FINANCIALS
Slide 33: Consolidated Profit & Loss
Consolidated Profit & Loss (₹ in Crores) H2FY26 H2FY25 YoY % FY26 FY25 YoY% Revenue from Operations 110.62 87.13 26.96 200.70 162.92 23.19 Employee Expenses 11.51 13.72 - 22.98 27.60 - COGS 9.05 4.86 - 14.47 8.99 - Other Expenses 75.19 59.95 - 138.55 112.09 - EBITDA 14.87 8.60 72.91 24.69 14.23 73.5
Slide 34: Balance Sheet
Balance Sheet (₹ in Crores) Particulars March 2026 March 2025 March 2024 Equity Capital 16 16 3 Reserves 51.85 36 7 Borrowings 2.41 6 2 Other Liabilities 14.83 7 11 Total Liabilities 84.85 65 22 Fixed Assets 11.21 7 3 CWIP 0.78 0.28 0 Investments 0.52 0.82 5 Other Assets 72.33 58 14 Total Assets 84.
Slide 35: Get in touch
Get in touch info@satkartar.in AYUSH DIVECHA G12-14, 7th Floor- Commerce Centre, Mumbai- 400034 Email : ir@merlincapital.co.in Contact : +91 81048 55515